Autoimmune & Inflammatory
Also called Behcet's Disease, Behçet's Syndrome
Behçet Disease is a chronic, recurrent systemic vasculitis affecting small, medium, and large vessels of multiple organ systems. The pathophysiology involves abnormal T cell activation, increased Th1/Th17 responses, and immune complex deposition leading to vessel inflammation.
Behçet Disease typically manifests in the second and third decades of life, though it can present at any age. It affects males more severely than females in some populations, though prevalence is roughly equal. The disease predominantly affects people from Turkey, Iran, Japan, Korea, China, Middle East, and Mediterranean regions. It is rare in Northern European and North American populations. HLA-B51 positive patients tend to have more severe disease.
Clinical trials for Behçet Disease focus on TNF inhibitors (infliximab, etanercept, adalimumab), which have shown efficacy in reducing disease activity, particularly for ocular and neurologic manifestations. Trials investigate IL-6 inhibitors, IL-17 inhibitors, and other biologic therapies. Trials examine optimization of immunosuppressive regimens and development of new targeted therapies. Management requires ophthalmologic involvement for disease monitoring and preventing vision loss. Patients should consult with rheumatologists or specialists experienced in managing Behçet disease.
Takayasu Arteritis is a rare chronic inflammatory disease of large arteries, particularly the aorta and its branches, ca...
Giant Cell Arteritis is a rare inflammatory disease of large and medium-sized arteries, primarily affecting people over ...
Granulomatosis with Polyangiitis is a rare autoimmune disease causing inflammation of small and medium blood vessels in ...